Novonesis (Novozymes) stock (DK0060336014): biotech merger reshapes enzymes and ingredients leader

Novonesis, the biosolutions group created from the merger of Novozymes and Chr. Hansen, continues to integrate its enzyme and microbial ingredient portfolios and update investors on post-deal progress. The company recently outlined synergy expectations and cost impacts from the combination in investor materials and regulatory filings, framing 2024 as a key year for executing the merger plan, according to Novonesis company announcements as of 04/2024 and Novonesis investors as of 03/2024.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

Novonesis: core business model

Novonesis describes itself as a biosolutions company built on the heritage of Novozymes and Chr. Hansen. Both legacy firms focused on using microorganisms and enzymes to replace or improve traditional chemical and resource-intensive processes, and the combined group aims to extend that model across a broad portfolio of food, agriculture and industrial applications, according to Novonesis about as of 02/2024.

The business model centers on developing patented enzymes, cultures, probiotics and other biological inputs that customers integrate into their own products or manufacturing processes. Revenue is typically generated through long-term supply relationships with consumer goods companies, food manufacturers, agricultural firms and industrial customers that rely on consistent quality, technical support and innovation. This positions the company as a specialty supplier rather than a consumer-facing brand.

Because many applications address efficiency, sustainability or product performance, Novonesis focuses on demonstrating quantifiable benefits such as higher yields, lower use of raw materials or energy, or improved taste and shelf life. That value proposition can support premium pricing and stickier customer relationships, but it also requires ongoing R&D investment and close collaboration with customers to adapt solutions to specific processes.

From a financial perspective, biosolutions businesses are often characterized by relatively high gross margins but meaningful spending on research, application development and technical service. The merger is designed to spread those fixed costs over a larger revenue base and to create a broader portfolio that can be cross-sold into overlapping customer segments, according to Novonesis company announcements as of 01/2024.

Main revenue and product drivers for Novonesis (Novozymes)

One of the largest revenue contributors for Novonesis is enzymes and cultures used in food and beverage production. Applications include baking, dairy, plant-based foods, beverages and fermentation-based products. Enzymes can help bakers achieve consistent quality and extended freshness, while cultures and probiotics support flavor development, texture and potential health-related features in dairy and alternative products, according to legacy materials from Novozymes as of 11/2023.

Agriculture and animal health products form another important revenue stream. Microbial solutions and enzymes can be used in crop treatments, silage management and animal feed, where they aim to improve nutrient utilization, yields and environmental footprints. These products are often sold through agricultural distribution networks and feed manufacturers, creating a mix of direct and indirect sales channels for the company.

Household care and industrial applications also play a significant role. Enzymes used in laundry detergents and other cleaning products are designed to improve stain removal at lower temperatures, which can reduce energy use for consumers. Industrial enzymes are used in areas like biofuels, textile processing, pulp and paper, and other process industries, where they can enable more efficient and less resource-intensive operations, according to Novozymes industries overview as of 10/2023.

The merger with Chr. Hansen added a significant probiotics and microbial ingredients portfolio, particularly in human health, animal health and food cultures. These products are used in dietary supplements, functional foods and specialty food production, diversifying the group’s exposure beyond industrial enzymes. Management has positioned the combined portfolio as an integrated biosolutions platform that can serve customers seeking both performance and sustainability benefits in their products and processes.

For US-focused investors, it is relevant that Novonesis supplies enzymes and microbial solutions to multinational consumer goods and food companies with substantial operations in North America. While the primary listing is in Copenhagen, the group’s revenue base is geographically diversified, and demand from US food, agriculture and consumer product markets is an important driver of overall performance, according to regional breakdowns discussed in past investor presentations from Novozymes investor as of 11/2023.

Conclusion

Novonesis brings together two established biosolutions franchises in enzymes and microbial ingredients, and 2024 remains an important period for capturing merger synergies and managing integration costs. The group’s exposure to food, agriculture, household care and industrial customers gives it a diversified revenue base, including meaningful links to the US consumer and industrial economy. For investors watching European-listed biotech and specialty chemicals names with global reach, the stock represents an example of how biological solutions are being scaled into mainstream industrial and consumer value chains, while also carrying the usual execution, demand and competitive risks that accompany a major integration.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.